Maravai Lifesciences Holdings, Inc. (MRVI): Cost of Revenue
$151.75M
Year ended 2025-12-31
$135.93M
Trailing 12 months to 2026-06-30
-3.5%
3-year compound annual growth
+13.8%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $151.75M | +0.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $150.88M | +1.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $148.74M | -12.0% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $168.96M | +20.2% | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | $140.56M | +76.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $79.65M | +19.1% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $66.85M | n/a | 2022-03-01, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $40.97M | -8.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $19.49M | +45.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $93.12M | +6.9% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $22.60M | +183.4% |
| Liquidia Corp (LQDA) | 2024-12-31 | $5.88M | +103.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $41.35M | +7.0% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $58.16M | -9.7% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $0 | -100.0% |
Compare MRVI, LFVN, RYTM, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗